NCT02246764

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 12-month Study Assessing the Safety of AR-13324 Ophthalmic Solution, 0.02% QD & BID Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pressure

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 93 (actual)
• Sponsor: Aerie Pharmaceuticals · Industry
• Sex: All
• Age: 19 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the ocular and systemic safety of Netarsudil (AR-13324) Ophthalmic Solution, 0.02% q.d. and b.i.d. for 12 months compared to the active comparator Timolol Maleate Ophthalmic Solution, 0.5%.

Conditions

• Ocular Hypertension
• Glaucoma

Interventions

Type	Name	Description
DRUG	AR-13324 Ophthalmic Solution 0.02%	1 drop once daily (QD), PM, OU
DRUG	AR-13324 Ophthalmic Solution 0.02% BID	1 drop BID, AM/PM, OU
DRUG	Timolol maleate Ophthalmic Solution 0.5% BID	1 drop BID, AM/PM, OU
OTHER	Placebo	1 drop QD, AM, OU

Timeline

• Start date: 2014-09-01
• Primary completion: 2016-12-01
• Completion: 2016-12-01
• First posted: 2014-09-23
• Last updated: 2018-04-06
• Results posted: 2018-04-06

Locations

1 site across 1 country: United States